An Open Label Phase II Study of the Efficacy and Tolerability of PRL3-ZUMAB and Predictive Biomarkers in Advanced Solid Tumours
Latest Information Update: 13 Jun 2025
At a glance
- Drugs PRL3 ZUMAB (Primary)
- Indications Gastric cancer; Liver cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 17 Jan 2024 Planned End Date changed from 1 Jun 2024 to 31 Dec 2025.
- 17 Jan 2024 Planned primary completion date changed from 1 Jun 2024 to 31 Dec 2025.
- 10 Jun 2022 Planned End Date changed from 1 Dec 2021 to 1 Jun 2024.